Shareholder Class Action

     CHICAGO — Directors are selling Sagent Pharmaceuticals too cheaply through an unfair process to Nichi-Iko Pharmaceutical, for $21.75 a share or $714 million, shareholders claim in Federal Court.

%d bloggers like this: